The combination of broadly neutralizing antibodies and viral inducers can suppress the establishment of HIV-1 latent reservoir


Antiretroviral therapy (ART) has been a effective strategy for suppressing HIV-1 infection. However, the effect of ART is withdrawn because of latent reservoirs of HIV-1-infected cells, which can live for a long time, invisible to immune system, and may undergo homeostatic proliferation. Since all attempts to alter the HIV-1 reservoir in vivo by combining ART with viral inducers have failed to date, Halper-Stromerg et al. demonstrated that broadly neutralizing antibodies (bNAbs) can suppress the establishment of a silent reservoir in humanized mice. The article was published in Cell.


In the presence of inducers of viral transcription, researchers determined the effects of bNAbs on the formation of latent reservoir, and found bNAbs interfere with the formation of reservoir via Fc-FcR-mediated mechanisms. Although bNAbs or bNAbs with single inducers failed for preventing viral rebound, bNAbs with a combination of inducers were proved to suppress the formation of latent reservoir by the measurement of viral rebound. The findings provide a novel therapeutic strategy that combines inducers with bNAbs for interfering with the formation and maintenance of HIV-1 latent reservoir.


Cell. 2014 Aug 28;158(5):989-99.

Related Products

Cat.No. Product Name Information
S1047 Vorinostat (SAHA) Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683, Zolinza) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.

Related Targets

Autophagy HDAC